electroCore reports record FY2022 net sales of $8.6M, up 58%; guides FY2023 revenue $14-15M

electroCore, Inc.

Record full-year net sales of $8.6M (+58% YoY); Q4 net sales $2.6M (+72% YoY).
GAAP net loss $22.2M vs $17.2M in 2021; Adjusted EBITDA loss $19.0M vs $15.8M.
Cash and equivalents $18.0M at Dec 31, 2022, down from $34.7M at Dec 31, 2021.
FY2023 guidance: revenue $14-15M; legacy headache channels >$12M; new Truvaga/TAC-STIM >$2M.
Launched Truvaga wellness product and TAC-STIM under Air Force program; distribution deal with Joerns.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

electroCore, Inc. reported financial results for fourth quarter and full year ended December 31, 2022.

Period: fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 8, 2023, electroCore, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2022. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

electroCore, Inc. reported full year 2023 results: revenue $14.0 - $15.0 million. Guidance initiated.

Period: full year 2023
Revenue: $14.0 - $15.0 million
Guidance: initiated
Result: guidance update

Exact text from the filing

The Company expects net revenue for the full year 2023 to be in the range of $14.0 - $15.0 million.

View on SEC.gov

Browse all earnings releases →

electroCore, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-018557

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.